Clinical Trials Directory

Trials / Completed

CompletedNCT01628731

Furosemide Versus Ethacrynic Acid in Children With Congenital Heart Disease

Phase III Study of Furosemide Continuous Infusion Versus Ethacrynic Acid Continuous Infusion in Children Undergoing Cardiac Surgery: Randomized Double Blind Controlled Clinical Trial

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
74 (actual)
Sponsor
Bambino Gesù Hospital and Research Institute · Academic / Other
Sex
All
Age
10 Years
Healthy volunteers
Not accepted

Summary

This study aims to verify if ethacrynic acid continuous infusion is superior to furosemide continuous infusion in total urine output production during the first 24 post operative hours.

Detailed description

Diuretic therapy in children after open heart surgery is widely administered, though no evidence currently supports if an ideal drug or an ideal dosage can be recommended. Loop diuretics are the most effective drugs in terms of urine output production but may cause some collateral effects such as metabolic alkalosis, hypovolemia, hypokalemia, ototoxicity. Furthermore, some reports showed that loop diuretics usage can be associated with an increased risk of renal dysfunction and mortality. However, their use in children with signs of fluid overload, pulmonary edema or oliguria is mandatory and widely practiced. Furosemide and ethacrynic acid are often prescribed and administered without any specific indication, basing on clinicians preferences. No study so far, explored the hypothesis of which of these drugs is the most effective in terms of urine output production and safe in terms of renal function. This study aims to verify if ethacrynic acid continuous infusion is superior to furosemide continuous infusion in total urine output production during the first 24 post operative hours.

Conditions

Interventions

TypeNameDescription
DRUGfurosemidefurosemide, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
DRUGethacrynic acidethacrynic acid, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours

Timeline

Start date
2012-10-01
Primary completion
2013-07-01
Completion
2013-11-01
First posted
2012-06-27
Last updated
2014-07-24

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT01628731. Inclusion in this directory is not an endorsement.